Logistics

Continuity of care is generally defined in terms of a patient’s ongoing contact with a clinical team and how smoothly their care progresses between providers. Often overlooked is the pharma supply chain and its role in ensuring this continuity. read more

The pharmaceutical industry is entering a period of intensified trade disruption. With new tariffs on imported raw materials, active pharmaceutical ingredients (APIs), and medical components, global supply chains that once prioritized efficiency are now facing rising costs, increased complexity, and growing regulatory risk. For companies developing biologics and Antibody-drug conjugates (ADCs), the impact is particularly acute. read more

The pharmaceutical supply chain faces unprecedented complexity in 2025, balancing accelerating scientific innovation with mounting operational and regulatory pressures. Below, we analyze critical challenges, regulatory shifts, and emerging technologies reshaping this $1.5 trillion global industry. read more

Cambrex has broken ground on a $120 million expansion at its Charles City, Iowa facility. The project will add 160,000 liters of manufacturing capacity, increasing the site's total capacity by approximately 25% to nearly one million liters. read more

Samsung Biologics has achieved a 'Negligible Risk' rating in the latest Morningstar Sustainalytics ESG Risk Ratings assessment. The CDMO received an ESG Risk Rating score of 9.0, advancing from its previous 'Low Risk' rating to 'Negligible Risk,' the lowest of five risk categories. read more

Lonza has signed a definitive agreement to acquire five CDMO manufacturing sites in the US from Merck KGaA, Darmstadt, Germany, at a total enterprise valuation in the low- to mid-triple-digit millions Swiss francs. The deal more than doubles Lonza's US CDMO footprint from four to nine sites. read more

This eBook explores how advanced therapy developers can scale efficiently by shifting from fixed infrastructure to flexible, elastic supply chain models. read more